Use of transgenic mice to study the role of apolipoprotein E in lipid metabolism and atherosclerosis

International Journal of Tissue Reactions

Volumn 22, Issue 2-3, 2000, Pages 49-58

  Willems Van Dijk, K ^a   Hofker, M H ^a   Havekes, L M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ANIMAL DISEASE; ANIMAL MODEL; ATHEROSCLEROSIS; CELL TRANSFER; GENE TECHNOLOGY; KNOCKOUT MOUSE; LIPID METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUANTITATIVE HISTOCHEMISTRY; REVIEW; SOMATIC CELL GENETICS; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; HUMANS; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, TRANSGENIC; TRIGLYCERIDES;

EID: 0033915563     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Apolipoprotein E as a risk factor for coronary heart disease: A genetic and molecular biology approach
2. Apolipoprotein E polymorphism in The Netherlands and its on plasma lipid and apolipoprotein levels
3. Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism
4. The role of apolipoprotein E genetic variants in lipoprotein disorders
5. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigenerational pedigree
6. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E
7. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
8. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice
9. Atherosclerosis in mice lacking apo E: Evaluation of lesional development and progression
10. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E
11. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia
12. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
13. Atherosclerosis in APOE*3-Leiden transgenic mice: From proliferative to atheromatous stage
14. Elevated levels of chylomicron- and VLDL-remnants leads to atherosclerosis in apoE transgenic mice
15. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
16. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 → Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice
17. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein
18. Inducible inactivation of hepatic LRP Gene by Cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants
19. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins
20. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2
21. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE
22. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice
23. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor
24. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans
25. Hepatic apoE expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor
26. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE-3 allele enhances diet-induced hypercholesterolemia and atherosclerosis
27. Apo E structure determines VLDL clearance and atherosclerosis risk in mice
28. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes
29. Apolipoprotein E controls a rate-limiting step in very low density lipoprotein secretion by mouse liver cells
30. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia
31. Inefficient degradation of triglyceride-rich lipoprotein by HepG2 cells is due to a retarded transport to the lysosomal compartment
32. Recycling of apolipoprotein E in mouse liver
33. Triglyceriderich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146→Gln) are inefficiently converted to cholesterol-rich lipoproteins
34. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1
35. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner
36. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo
37. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146→Gln) Allele carriers
38. The pathogenesis of atherosclerosis: A perspective for the 1990s
39. Expression of the VLDL receptor in endothelial cells
40. Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity
41. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor
42. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery
43. Apolipoprotein E secretion by macrophages: Its potential physiological functions
44. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice
45. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation
46. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E- deficient mouse plasma
47. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages
48. Elimination of macrophage-specific apolipoprotein E reduces diet-induced atherosclerosis in C57BL/6J male mice
49. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides
50. Hyperlipidemia of APOE-2(arg158-cys) and APOE-3-Leiden transgenic mice is predominantly modulated by low density lipoprotein receptor expression